A leading pharmaceutical company headquartered in China with integrated R&D, manufacturing, marketing, sales and distribution capabilities. The firm operates as a subsidiary of a publicly traded pharmaceutical company. The firm has a strong pipeline in liver diseases, oncology, respiratory diseases and is one of the top pharmaceutical companies in China within these domains. In addition, the firm has strong interest in CNS diseases, metabolic diseases, etc. With extensive experience and successful records of in and out licensing and co-development ventures with oversea companies, the firm is interested in collaborating with oversea companies whose assets align with its current pipeline and areas of interest. The firm is open to a wide range of partnership and capital structures, including co-development, in/out-licensing, equity investments and acquisitions. The firm is interested in opportunities globally.
The firm is interested in therapeutic assets that align with their areas of focus, which include liver diseases, oncology, respiratory disease, CNS disease, metabolic diseases. The firm is open to various modalities within therapeutics, with a particular emphasis on both large and small molecule drugs. The firm seeks assets ranging from pre-clinical to early-clinical stages (Phase I/Phase Ib), but is also open to considering later-stage assets that align well with their scope of interest.
The firm does not have any specific requirement for the company and the management team.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment